Australia markets closed

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.05000.0000 (0.00%)
At close: 04:00PM EDT
3.0400 -0.01 (-0.33%)
After hours: 07:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0500
Open3.0600
Bid3.0400 x 200
Ask3.0700 x 200
Day's range3.0400 - 3.1700
52-week range2.4500 - 4.1390
Volume137,784
Avg. volume211,693
Market cap215.665M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-0.7400
Earnings date03 May 2024 - 07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.20
  • Simply Wall St.

    Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying

    Last week, Ovid Therapeutics Inc. ( NASDAQ:OVID ) insiders, who had purchased shares in the previous 12 months were...

  • GlobeNewswire

    Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

    Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024OV888 (GV101) is progressing on-track in a Phase 1, double-blind, multiple-ascending dose trial; a higher dose cohort has been added and no serious adverse events have been observed Feedback from a pre-IND session with the FDA supports potential initiation of a Phase 2 study of O

  • GlobeNewswire

    Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen panel discussion can b